Commonwealth Psychology is now LifeStance Health! Clients will continue to receive the same comprehensive and compassionate care with the same insurance coverage. This site will soon redirect to a site our new online home where you’ll find access to our online scheduling, expanded resources, and important information.CURRENT CLIENTS click here to register for your NEW secure portal account today!
There is a new version of an ADHD treatment drug that may be less prone to abuse and addiction.
Neurovance, a clinical neuroscience company, has altered the way an existing drug, called centanafadine, works so that it creates adverse feelings and symptoms initially, prior to the more positive feelings that often occur with stimulant use. They believe the initial experience of negative feelings and symptoms lowers the likelihood of patients abusing the medication.
One of the problems with today’s ADHD treatment drugs is that they come with signifiant addiction and abuse risk. These risks often lead psychiatrists and prescribers to avoid using these medications with clients who have a history of abuse or misuse of medication (college students selling their medications). As such, having a new option with lower risk of abuse would represent a significant advancement in the treatment of ADHD, particularly among college students and young adults.
If you believe that you may have ADHD, neuropsychological testing for ADHD can help diagnose ADHD and aid in treatment planning.
Excerpt from press release and related link below.
The drug, a sustained-release version of the drug that goes by the generic name of centanafadine, affects the activity of three hormones — norepinephrine, dopamine and serotonin — in neurotransmitters known to be relevant in patients with ADHD.
The company said that testing with self-admitted recreational drug users showed that when the drug is released at higher doses – such as would occur if the sustained-release of the developed drug was tampered with — the drug caused an onset of negative side-effects before the positive effects of the amphetamine were felt, with subjects reporting nausea, vomiting and dysphoria. There were 80 test subjects in the study, according to clinicaltrials.gov.
October 30, 2019|ADHD
Commonwealth Psychology Associates® (CPA) has recently expanded child & adolescent behavioral health services into our North Station office, located…Read More
February 5, 2019|ADHD
What is neuropsychological testing? A useful tool for accurately diagnosing ADHD, learning disabilities, a neuropsychological evaluation is a comprehensive assessment…Read More